Is OM-3 Synergistic with GLP-2 in Intestinal Failure?

Introduction GLP-2is a known intestinal growth factor that enhances mucosal mass and function in residual small intestine(SI) after massive small bowel resection. Luminal OM-3 has been shown to have some growth factor properties. It is possible that their mechanisms of action differ. Thus, we hypoth...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of surgical research 2017-01, Vol.207, p.7-12
Main Authors: Karmaker, Avik, MD, Costanzo, Caitlyn M, Schwartz, Marshall Z
Format: Article
Language:English
Subjects:
Animals
Biomarkers - metabolism
Bowel adaptation
DNA - metabolism
Drug Synergism
Drug Therapy, Combination
Fatty acid
Fatty Acids, Omega-3 - pharmacology
Fatty Acids, Omega-3 - therapeutic use
Female
Gastrointestinal Agents - pharmacology
Gastrointestinal Agents - therapeutic use
GLP-2
Glucagon-Like Peptide 2 - pharmacology
Glucagon-Like Peptide 2 - therapeutic use
Glucagon-like Peptide-2
Intestinal Absorption - drug effects
Intestinal adaptation
Intestinal failure
Intestinal Mucosa - drug effects
Intestinal Mucosa - metabolism
Intestine, Small - drug effects
Intestine, Small - metabolism
MSBR
OM-3
Omega-3
Rats
Rats, Sprague-Dawley
Short Bowel Syndrome - drug therapy
Short Bowel Syndrome - metabolism
Short gut syndrome
Surgery
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction GLP-2is a known intestinal growth factor that enhances mucosal mass and function in residual small intestine(SI) after massive small bowel resection. Luminal OM-3 has been shown to have some growth factor properties. It is possible that their mechanisms of action differ. Thus, we hypothesized that administering these two substances together may have a synergistic effect. Methods 60 adult female Sprague-Dawley rats underwent 80% MSBR and divided as follows (N=15/group): Saline(Control)+regular feeds(RF); GLP-2+RF; Saline+OM-3 enriched feeds; GLP-2+OM-3. 5 animals per group were sacrificed at 7, 14, and 28 days. SI mucosa was harvested. DNA and protein content were measured(mucosal mass markers). Galactose and Glycine absorption were measured(functional capacity markers) at 28 days. Statistical analysis was done by ANOVA with post-hoc Tukey’s HSD test. Results DNA content: At all three time points DNA was increased in all treatment groups compared to control(p
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2016.08.018